The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Sirius Therapeutics 靖因藥業 * (Incorporated in the Cayman Islands with limited liability) WARNING The publication of t ...

Summary of Suzhou Ribo Life Science (6938.HK) Conference Call Company Overview - **Company**: Suzhou Ribo Life Science - **Ticker**: 6938.HK - **Industry**: siRNA Drug Development Key Points Industry and Market Potential - The global oligonucleotide drug market is projected to grow from **US$5.7 billion in 2024** to **US$54.9 billion by 2034**, with a CAGR of **29.4% from 2024 to 2029** and **21.6% from 2029 to 2034** [28][29] - siRNA drugs are expected to capture a greater market share, outpacing other oligonucleotide modalities [28] Company Strengths - Ribo is a pioneer in siRNA technology with a robust pipeline of **seven in-house discovered drug assets** in clinical trials targeting cardiovascular, metabolic, renal, and liver diseases [12][3] - Proprietary delivery technologies, including **RiboGalSTARTM**, enhance targeting specificity and safety, positioning Ribo as a leader in siRNA therapeutics [25][26] - Collaborations with major pharmaceutical companies, including **Boehringer Ingelheim** and **Madrigal**, with total deal value exceeding **US$6.0 billion** [4][26] Key Products - **RBD4059**: A potential first-in-class FXI-targeting siRNA drug for thrombotic diseases, with estimated peak sales potential of **US$6.8 billion** [2][15] - **RBD5044**: A potential best-in-class APOC3-targeting siRNA for hypertriglyceridemia, showing competitive triglyceride-lowering efficacy [21] - **RBD1016**: A promising siRNA candidate for chronic hepatitis B (CHB) and coronary heart disease (CHD), with favorable safety and efficacy profiles [22][23] Financial Overview - **2023 Net Profit**: -RMB 428 million - **2024 Net Profit**: -RMB 270 million, with an expected EPS growth of **36.9%** [5][9] - **Target Price**: HK$102, representing an expected share price return of **73.5%** [6][11] Clinical Development and Efficacy - RBD4059 has shown a **dose-dependent reduction** in FXI activity, with maximum percentage changes from baseline of **67.5% to 91.6%** across different dosing cohorts [37] - The phase 2a trial for RBD4059 is expected to complete by the end of **2025** [35] Risks and Challenges - Key risks include potential R&D failures, slower-than-expected product launches, competition, and historical lack of profitability [4][11] Conclusion - Suzhou Ribo Life Science is positioned as a leader in the siRNA therapeutic space with significant growth potential driven by innovative products and strategic collaborations. The company faces challenges typical of biotech firms, including the need for successful clinical outcomes and market acceptance.

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Sirius Therapeutics 靖因藥業 * (Incorporated in the Cayman Islands with limited liability) WARNING The publication of t ...